All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How do we differentiate high-risk MDS from AML?

Aug 9, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in MDS.

During the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk MDS from AML?

How do we differentiate high-risk MDS from AML?

De Witte begins by explaining the implications of the new International Prognostic Scoring System (IPSS) for MDS, and the flaws of existing risk-based scoring systems. De Witte then discusses the data from the patient cohort used to develop the new IPSS, including the most relevant genetic predictors of adverse and favorable outcomes. De Witte also talks about the parameters that can be given by the IPSS calculator.


Subscribe to get the best content related to MDS delivered to your inbox